Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

The Lancet Haematology

Volumn 3, Issue 12, 2016, Pages e581-e591

  Cortes, Jorge E ^a   De Souza, Carmino Antonio ^b   Ayala, Manuel ^c   Lopez, Jose Luis ^d   Bullorsky, Eduardo ^e   Shah, Sandip ^f   Huang, Xiaojun ^g   Babu, K Govind ^h,i   Abdulkadyrov, Kudrat ^j   de Oliveira, José Salvador Rodrigues ^k   Shen, Zhi Xiang ^l   Sacha, Tomasz ^m   Bendit, Israel ⁿ   Liang, Zhizhou ^o   Owugah, Tina ^p   Szczudlo, Tomasz ^p   Khanna, Sadhvi ^q   Fellague Chebra, Rafik ^r   le Coutre, Philipp D ^s  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d Esq Pirineos   (Venezuela)

^e HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^f GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

^g PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^h KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

ⁱ Health Care Global Enterprises   (India)

^j Russian Research Institute of Hematology and Transfusiology   (Russian Federation)

^k FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^l SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^m JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

ⁿ UNIVERSITY OF SÃO PAULO   (Brazil)

^o Guangzhou KingMed Center for Clinical Laboratory   (China)

^p NOVARTIS PHARMA AG   (Switzerland)

^q Novartis Healthcare Pvt Ltd   (India)

^r Novartis Pharma SA   (France)

^s CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; NILOTINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; PHARMACOLOGICAL BIOMARKER; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; ELECTROCORTICOGRAPHY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; ADVERSE DRUG REACTION; ASIA; BONE MARROW; CHEMICALLY INDUCED; CHEMISTRY; CHROMOSOME ANALYSIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE EFFECTIVENESS; DISEASE EXACERBATION; DRUG EFFECTS; EUROPE; FEVER; HEMATOLOGIC DISEASE; METABOLIC DISORDER; MIDDLE AGED; MORTALITY; MYELOID LEUKEMIA; PHILADELPHIA 1 CHROMOSOME; PROCEDURES; RANDOMIZATION; RASH; SOUTH AND CENTRAL AMERICA; STANDARDS; TREATMENT FAILURE;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC PROTOCOLS; ASIA; BIOMARKERS, PHARMACOLOGICAL; BONE MARROW; COMPARATIVE EFFECTIVENESS RESEARCH; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPE; EXANTHEMA; FEMALE; FEVER; FOLLOW-UP STUDIES; HEADACHE; HEMATOLOGIC DISEASES; HUMANS; IMATINIB MESYLATE; LATIN AMERICA; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; METABOLIC DISEASES; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PYRIMIDINES; RANDOM ALLOCATION; TREATMENT FAILURE;

EID: 84997634541     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(16)30167-3     Document Type: Article

References (27)

1. 1 Baccarani, M, Cortes, J, Pane, F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27 (2009), 6041–6051.
2. 2 Quintas-Cardama, A, Kantarjian, H, Jones, D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113 (2009), 6315–6321.
3. 3 Hughes, TP, Hochhaus, A, Branford, S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS). Blood 116 (2010), 3758–3765.
4. 4 Alvarado, Y, Kantarjian, H, O'Brien, S, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 115 (2009), 3709–3718.
5. 5 Kantarjian, H, O'Brien, S, Shan, J, et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. Cancer 112 (2008), 837–845.
6. 6 Marin, D, Milojkovic, D, Olavarria, E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 112 (2008), 4437–4444.
7. 7 Druker, BJ, Guilhot, F, O'Brien, SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006), 2408–2417.
8. 8 Baccarani, M, Deininger, MW, Rosti, G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122 (2013), 872–884.
9. 9 Saglio, G, Kim, DW, Issaragrisil, S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362 (2010), 2251–2259.
10. 10 Kantarjian, H, Shah, NP, Hochhaus, A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362 (2010), 2260–2270.
11. 11 Jabbour, E, Kantarjian, HM, Saglio, G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123 (2014), 494–500.
12. 12 Hughes, TP, Saglio, G, Kantarjian, HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123 (2014), 1353–1360.
13. 13 Marin, D, Ibrahim, AR, Lucas, C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30 (2012), 232–238.
14. 14 Hanfstein, B, Muller, MC, Hehlmann, R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26 (2012), 2096–2102.
15. 15 Deininger, M, O'Brien, SG, Guilhot, F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood, 114(suppl), 2009 abstr 1126.
16. 16 Jabbour, E, Kantarjian, H, O'Brien, S, et al. The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors. Blood 11:8 (2011), 4541–4546.
17. 17 Press, RD, Love, Z, Tronnes, AA, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 107 (2006), 4250–4256.
18. 18 Milojkovic, D, Nicholson, E, Apperley, JF, et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 95 (2010), 224–231.
19. 19 Giles, FJ, le Coutre, PD, Pinilla-Ibarz, J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 27 (2013), 107–112.
20. 20 Shah, NP, Guilhot, F, Cortes, JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study. Blood 123 (2014), 2317–2324.
21. 21 Jabbour, E, Kantarjian, H, Ghanem, H, et al. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure. Clin Lymphoma Myeloma Leuk 13 (2013), 302–306.
22. 22 Tanimoto, M, Miyamura, K, Miyamoto, T, et al. Final results from SENSOR: switch to nilotinib after molecular suboptimal response (SoR) to frontline imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP). Blood, 124(suppl), 2014 abstr 1815.
23. 23 Hughes, TP, Hochhaus, A, Kantarjian, HM, et al. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300 mg twice daily. Haematologica 99 (2014), 1204–1211.
24. 24 Kantarjian, HM, Larson, RA, Guilhot, F, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115 (2009), 551–560.
25. 25 Kantarjian, HM, Giles, F, Gattermann, N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110 (2007), 3540–3546.
26. 26 Cortes, JE, Saglio, G, Baccarani, M, et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood, 124(suppl), 2014 abstr 152.
27. 27 Hochhaus, A, Saglio, G, Hughes, TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30 (2016), 1044–1054.